Temporally Expressed PDGF and FGF-2 Regulate Embryonic Coronary Artery Formation and Growth

Robert J. Tomanek, Heidi K. Hansen, Lance P. Christensen

Objective—PDGF and FGF-2 are important regulators of vascular wall assembly. We tested the hypothesis that their embryonic temporal expression facilitates 2 specific events: (1) the endothelial invasion of the aortic root to form the coronary artery stems and (2) the subsequent growth and development of the arterial tree.

Methods and Results—Addition of FGF-2 and PDGF-BB proteins to embryonic quail heart explants stimulated a 3- and 7-fold increase, respectively, in tubulogenesis, whereas neutralizing antibodies to these growth factors attenuated tubulogenesis by 40%. Anti–FGF-2 and anti-PDGF neutralizing antibodies were then introduced in ovo via the vitelline vein at various embryonic (E) days. When injections occurred before coronary ostial formation, the embryos usually developed only 1 coronary artery or lacked coronary arteries. When 1 or both major coronary arteries formed: (1) their branches had a thinner tunica media, and (2) smooth muscle investment did not progress as far distally as in shams. Other anomalies included smaller diameter coronary artery stems in some hearts. Inhibition of VEGF via injections of aflibercept (VEGF-Trap, a VEGFR-1 and -2 chimera), previously shown to be essential for coronary stem formation, limited development of the coronary arteries even though introduced after formation of coronary ostia (at E9 or E10).

Conclusions—Our data (1) document a role for FGF-2 and PDGF in the temporal regulation of coronary artery stem formation and growth of the coronary arterial tree and (2) reveal that VEGF expression is required for normal artery/arterial formation, even after coronary artery stem formation. (Arterioscler Thromb Vasc Biol 2008;28:1237-1243)

Key Words: arteriogenesis ■ angiogenesis ■ VEGF ■ FGF-2 ■ PDGF ■ coronary arteries

Most contemporary studies regarding the formation of the coronary vasculature have focused on the formation of the epicardium, epithelial-mesenchymal transformation and factors regulating coronary vascular cell differentiation (see reviews).1,2 They demonstrated that epicardially-derived cells differentiate into vascular phenotypes, ie, endothelial, smooth muscle, fibroblasts, and then migrate, proliferate, and assemble to form vascular channels. The role of growth factors in the regulation of the events that occur before coronary artery formation have also been investigated, ie, vasculogenesis (migration and assembly of endothelial cells or precursors to form vascular tubes) and angiogenesis (branching and extension of the vascular tubes). We have shown, both in vivo3,4 and in vitro5,6 that coronary tubulogenesis is facilitated by VEGF and FGF-2. Moreover, tubulogenesis correlates with an epi-to-endocardial VEGF protein gradient.7 Inhibition of VEGFs via aflibercept (VEGF Trap) markedly attenuates tubulogenesis when injected intravascularly in quail eggs on embryonic day 6, which corresponds to the onset of tubulogenesis. A role for FGF signaling in the development of a tubular plexus in mouse embryos has also been recently documented.8 That study showed that FGF triggers hedgehog (HH) activation, which is essential for VEGF-A, -B, and -C, and angiopoietin-2 expression. The authors noted that the embryonic myocardial vascularization was facilitated by the orchestration of multiple growth factors in response to HH activation.

However, little attention has been paid to the mechanisms regulating formation of the coronary arteries, which occurs subsequent to the formation of an endothelial-lined network, ie, embryonic (E) day 9 (HH 35) after a capillary-like peritruncal ring penetrates the aorta just above its valves to create the coronary ostia.9–12 Having found that VEGFR-2 and -3 mRNA transcripts are selectively dense at the sites of coronary artery stems during development,6 we inhibited VEGFs in quail embryos by injecting VEGF-Trap before the formation of the coronary ostia.9 These experiments revealed that the formation of coronary ostia and stems is dependent on VEGF family members, especially VEGF-B. The data from that study precipitate key questions regarding the roles of other growth factors, their temporal expression, and their interactions in both the formation and the growth of the coronary arterial vasculature.

Based on the concept that the coronary vasculature develops in response to temporally and spatially expressed growth factors acting in concert, we focused on 2 growth factors that are most likely to influence the recruitment and assembly of
vascular smooth muscle in the coronary arterial system, namely PDGFs and FGF-2. PDGF-BB plays a key role in endothelial cell proliferation,11 pericyte recruitment and survival,14 and the proliferation of mural cells and their precursors.15,16 A role for PDGF-BB and PDGFR-β in myocardial vasculogenesis/angiogenesis has been suggested because all cell types that contribute to the coronary vasculature express this ligand and receptor in the embryonic avian heart,17 and PDGF-BB enhances the production of VEGF in the myocardium.18 FGF-2 is a regulator of both angiogenesis and arteriogenesis (reviewed in Presta et al),19 as it has been shown to enhance endothelial and smooth muscle cell proliferation.20,21 We have documented a role for FGF-2 in embryonic myocardial tubulogenesis5 and postnatal arteriogenesis.4

The major goal of the current study was to test the hypothesis that PDGF and FGF-2 play a role in coronary artery formation in the embryo, but that their effects are temporal and specific with regard to (1) formation of the coronary ostia and (2) the development of the coronary arterial tree. A second goal was to document the temporal effects of PDGF and FGF-2 in coronary tubulogenesis. Finally, we also tested the hypothesis that VEGF plays a role in the development of the tunica media of coronary arteries.

Materials and Methods

Antibodies, Soluble Receptors, and Recombinant Proteins

Anti-PDGF and anti–FGF-2 neutralizing antibodies were purchased from R & D Systems. The anti-PDGF antibody shows a nearly 100% cross-reactivity with rh PDGF-BB, a 10% cross-reactivity with PDGF-AA, and a 60% cross-reactivity with PDGF-AB. Specificity of the FGF-2 antibody is indicated by data that reveal that it has <5% cross-reactivity with FGFs 2 to 6, 9, 10, 15, 17, 19. Aflibercept (VEGF-Trap), which binds ligands for VEGFR-1 (Flt-) and VEGFR-2 (Flk-1), is a VEGFR-1 and VEGFR-2 fusion protein that comprises portions of the human VEGF-1 and VEGF-2 extracellular domains fused to a constant region of human IgG1. Aflibercept was provided by Regeneron Pharmaceutical Inc. Recombinant human PDGF-BB and FGF-2 were purchased from R & D Systems and BD Biosciences, respectively.

Immunohistochemistry and Histology (In Vivo Studies)

All staining was done on serial cross-sections of the basal halves of the embryonic hearts. Endothelium was visualized by staining with QH1, a specific antibody for quail endothelium (University of Iowa Developmental Studies Hybridoma Bank), using Alexa 488-labeled goat antimouse IgG Fab a chromagen, as previously detailed.9,22 Addition of FGF-2 protein to the culture matrix.5,9 Addition of FGF-2 protein to the culture medium enhanced tubulogenesis nearly 7-fold in a dose-dependent manner (Figure 1A) consistent with our previously published data.5 PDGF-BB protein also increased tube formation, but only 3-fold. Addition of both growth factors enhanced tube formation but had an additive effect only at lower doses. Neutralizing antibodies to PDGF and FGF-2 each inhibited tubulogenesis by about 40% (Figure 1B). However, administration of the antibodies in combination did not enhance their inhibitory effect.

Temporal Effect of PDGF and FGF-2 on In Vivo Tubulogenesis

To determine the temporal effects of these growth factors on vasculogenesis/angiogenesis, we injected their neutralizing antibodies at 12 μg and 20 μg into the vitelline vein
on days E6, 7, 8, 9, and 10. The vascular volumes were then measured 2 days later. Both anti-PDGF and anti–FGF-2 at both doses significantly attenuated tubulogenesis when injected at E6, which corresponds to the onset of tubulogenesis in the myocardium (Figure 2). Vascular volume densities were 17% to 23% lower in the embryos injected with the antibodies at the 2 concentrations (12 and 20 μg/embryo), respectively. Injection of both anti-PDGF and anti–FGF-2 did not have an additive effect. When the embryos were injected at E7, E8, or E9, vascular volume was not affected. However, when both antibodies were injected at E9, vascular volume was 24% lower than the sham group. Injections of both antibodies at earlier time points had no significant effect.

Having previously documented the importance of VEGFs in early (E6, E7) tube formation,9 we tested the hypothesis that tubulogenesis continues to be influenced by VEGFs at later time points. Accordingly, VEGF-Trap was injected into embryos after the formation of the coronary artery stems and the establishment of the coronary circulation (E9 and E10). This intervention caused a 37% and 27% reduction in vascular volume density when injected at E9 and E10, respectively. Thus, VEGFs play a role in tubulogenesis after coronary artery stem formation, as well as during the early period of tubulogenesis.

**Inhibition of PDGF and FGF-2 Interrupts Formation of Main Coronary Arteries**

Injection of anti–FGF-2, anti-PDGF, and aflibercept (VEGF-Trap) in quail embryos caused a 37% and 27% reduction in vascular volume density when injected at E9 and E10, respectively. Thus, VEGFs play a role in tubulogenesis after coronary artery stem formation, as well as during the early period of tubulogenesis.

**Artery/Arteriolar Wall Assembly Is Attenuated by Temporal Inhibition of FGF-2 and PDGF**

Formation of coronary arteries occurs by the recruitment and assembly of vascular smooth muscle cells (SM) in a base to
apex direction; the earliest smooth muscle assembly is at the root of the 2 main coronary arteries. To determine the effect of FGF-2 and PDGF temporal inhibition on the progression of coronary artery/arteriolar formation, we used alternate sections stained with smooth muscle α-actin. We then noted the approximate most distal section from the base of the aorta in which an artery or arteriole was found (Figure 4). When neutralizing antibodies to FGF-2 and PDGF are injected at E6, the effect on muscularization of endothelial channels is most affected. This is consistent with the data that reveal most hearts treated with these antibodies either lack coronary artery stems or have only one. Delaying administration of the antibodies tends to lessen the inhibitory effect. Comparison of hearts from E10 embryos reveals 2 important findings. First, limitations in arterial/arteriolar growth attributable to anti–FGF-2 were greater when the antibodies were injected at E7 than when injected at E8. Second, the effects on arterial/arteriolar growth for all 3 antibody treatments were less marked in the hearts of E10 than in E9 quail. This finding suggests that inhibition of FGF-2 or PDGF at E7 does not arrest the muscularization process because E10 hearts tend to have better progression of medial development than E9 hearts.

The inhibitory effects of anti–FGF-2 and anti-PDGF on arterial/arteriolar development are illustrated in Figure 5. The examples provided show that the main effect is a poorly developed tunica media and most often larger diameters. At least this is true for the largest branches of the main coronary arteries (these are septal arteries).

VEGF Inhibition After Ostial Formation Limits Coronary Artery Assembly

Having previously documented that aflibercept prevents formation of the coronary artery stems, we injected this inhibitor at E9 and E10 ie, after the formation of the coronary stems, to determine the role of VEGFs in the progression of coronary artery and arteriolar growth. VEGF-Trap limited smooth muscle assembly of arteries and arterioles and the distance of muscularization of these vessels from the aortic root (data not shown). Thus, VEGFs (1) are required for the formation of both the coronary ostia and stems and (2) influence the development of the tunica media of the coronary arteries.

Phenotypes Induced by Anti–FGF-2 and Anti-PDGF

The compact region of the left ventricle is thinner in the hearts treated with the antibodies, compared to shams (Figure 6, L–O). The trabecular spongy component of the ventricular wall also tended to be more dominant, most notably when PDGF and FGF-2 were inhibited before E9 (Figure 6). The persistence of a sinusoidal system may be a compensation for an absence of or a limited coronary circulation. Other anomalies observed in some of the hearts of anti–FGF-2 and anti-PDGF treated embryos included (1) narrow coronary ostia, (2) multiple channels emerging from a coronary ostia, and (3) massive accumulations of blood cells either in the subepicardium or in the middle of the ventricular septum (Figure 6). These accumulations were previously documented in embryos

Figure 3. In vivo administration of anti–FGF-2 and anti-PDGF neutralizing antibodies limits coronary artery stem formation, such that neither stem or only 1 stem is formed. The neutralizing antibodies were injected on embryonic days 6, 7, 8, and studied 2 or 3 days later. The number of embryos is indicated within the bars.

Figure 4. Assessment of arterial/arteriolar growth. Data are the furthermost distance from the aortic base where arteries or arterioles were detected based on serial sections and smooth muscle α-actin immunostaining. For the purpose of standardization, the maximum distance included was 1000 μm.
treated with VEGF-trap and found to be derivatives of the proepicardium.

We did not find evidence for cellular alterations at the base of the aorta which might be related to limited ostial formation. Anti-PDGF and anti–FGF-2 treatments before ostial formation did not appear to limit (1) epicardial cell VEGF or cytokeratin immunoreactivity and (2) presence of subepicardial cell clusters, parasympathetic ganglia, and blood islands at the aorta (Figure 6). The overall growth of embryos treated with the inhibitors was not markedly

rounds the aorta and pulmonary artery in an anti–FGF-2 embryo (H); (3) ganglion cells (Ga) are seen near the mitral valve (Va) in an anti–PDGF embryo, and (4) the epicardial (arrow) and subepicardial cells at the aortic base in an anti–FGF-2–PDGF treated embryo retain their VEGF expression (J). Many VEGF-positive cells (arrows) are seen within the groove between the aorta and pulmonary artery in an anti–PDGF embryo (K). Treatment with anti–FGF-2 (M), anti–PDGF (N), or a combination of the 2 (O) leads to an exaggerated spongy layer (*) and a thinner compact layer compared to shams (L).
Discussion

Our previous in vivo studies on quail hearts revealed that VEGFR-2 and VEGFR-3 RNA transcripts are in high density at the sites of coronary artery stems and that the formation of coronary ostia and stems is dependent on VEGFs, especially VEGF-B. The current study has documented 3 major findings. First, administration of neutralizing antibodies to FGF-2 or PDGF frequently results in coronary anomalies including only 1 or no coronary artery stem, narrow coronary ostia, and multiple channels in the aorta contributing to a main coronary artery. We also provide both in vivo and in vitro evidence that these growth factors facilitate tubulogenesis during its early period (E6-E8). Second, our data support the conclusion that FGF-2 and PDGF each contribute to smooth muscle cell recruitment and the development of the tunica media. Neutralizing antibodies to these growth factors limit both distance from the ostia that smooth muscle cells are recruited and the thickness of the media. Third, VEGF, previously shown to be essential for coronary ostial formation, also facilitates smooth muscle recruitment after the coronary artery stems are formed, and continues to be a major regulator of microvessel (capillary) growth.

Vasculogenesis/Angiogenesis

As previously documented, tubulogenesis in quail hearts is first evident at E6.9,22 Endothelial precursor cells are responsive to growth factors at this stage as shown by our previous studies5,6 and by the current data. Our in vitro and in vivo data are in accord. The vasculogenic/angiogenic effect of PDGF-BB in heart explants revealed in this study may be attributable to the ability of PDGF-BB to induce marked increases in VEGF as demonstrated in rabbit hearts14 and retinal pigment cells.26 An earlier in vitro study showed that the PDGFR-β receptor is specific for endothelial tube formation and is responsive to PDGF-BB.13 Our in vitro data demonstrate that PDGF-BB enhances tube formation, but to a lesser degree than FGF-2, and that the effects of the 2 are additive only at suboptimal doses. The in vivo experiments support the hypothesis that the effects of FGF-2 and PDGF on tubulogenesis are temporally dependent, as evidenced by the data that indicate their influence wanes over time. However, when both are inhibited after a coronary circulation is established (E9), vascular volume is decreased. Thus, the forces associated with flow may influence the responses of endothelial cells to the 2 growth factors. In contrast, VEGF-Trap, shown previously to attenuate tubulogenesis when administered at E6 or E7,9 continued to be effective even when injected at E9 or E10.

Formation of the Coronary Ostia and Stems

The original observation in quail embryos describing the ingrowth of endothelial cells into the aortic wall was then detailed in the chick.12 The latter study described multiple penetrating channels with 2 channels becoming dominant to form the coronary ostia and stems at HH32. The process involves fusion of strands of the peritruncal ring of endothelial tubes and a disappearance of the tubes facing the noncoronary sinus.13 As documented in this study and previously,27,28 failure of ostial formation precludes myocyte recruitment of endothelial channels. Our data support a role for both FGF-2 and PDGF in ostial formation because neutralizing antibodies frequently either limited or prevented coronary artery stem formation. A recent study also reported abnormalities in the number of coronary ostia formed and thinner media of coronary arteries in PDGF-B knockout mouse embryos.29 As seen in Figure 3, the temporal effect was most evident when anti–FGF-2 or anti-PDGF was injected at E6 or E7; 20% or less of these embryos had 2 coronary artery stems. This is not surprising because penetration of the aorta by endothelial cells occurs in quail beginning at E7 or E8.11 The limitations in stem formation seen at E9 when anti–FGF-2 was administered at E7 are similar to those we previously reported.9

Although both PDGF-BB10 and FGF-211 effect VEGF secretion in endothelial cells, the mechanisms underlying their role in coronary ostial formation are still unclear. We did not detect changes in VEGF immunoreactivity of epicardial/subepicardial cells nor a loss of the capillary plexus at the aortic root. Furthermore, the presence of parasympathetic ganglia, which are considered essential for the development of coronary arteries,32 was also verified in the treated embryos. Thus, the anatomic environment at the aortic root does not appear to underlie failure of ostial formation in PDGF and FGF-2 inhibited embryos.

Formation of the Coronary Arterial Tree

The formation of the 2 vascular channels (coronary ostia) is immediately followed by mesenchymal cell recruitment to the sites of the forming coronary ostia and their differentiation in situ, an event that coincides with the abrupt onset of coronary flow and shear stress. Because shear stress differentially modulates FGF-2 and PDGF-BB in vascular cells,24 the effect of these growth factors may change when flow is initiated and smooth muscle cells give rise to coronary artery stems.11,22 A recent study in embryonic mice has suggested that the effect of FGF-2 on coronary artery formation is via a Wnt-FGF-2 pathway.35 We previously documented a role for FGF-2 in coronary arteriolar formation and growth during early postnatal development.4 That study also revealed that VEGF-A and FGF-2 together influence the hierarchy of the coronary arterial tree. The current finding that VEGF influences arteriolar growth, as well as capillary growth, coupled with our previous documentation that VEGF is required for coronary ostial and stem formation, supports the conclusion that this growth factor family plays a key role in events that span a broad period and several events of coronary vascularization.

Conclusions and Limitations of Study

The factors that orchestrate the events required to form the hierarchical coronary arterial tree are numerous and in-
volve complex interactions and signaling events. This study focused on growth factor regulation of ostial and coronary artery formation. Our main goal was to delineate the later stages of the cascade of events leading to the formation of the coronary arterial vasculature. We recognize that other molecules may also play key roles in this process. However, their delineation is beyond the scope of this study.

Sources of Funding

This work was supported by NIH grant 5 R01 HL 075446.

Disclosures

None.

References


Temporally Expressed PDGF and FGF-2 Regulate Embryonic Coronary Artery Formation and Growth
Robert J. Tomanek, Heidi K. Hansen and Lance P. Christensen

Arterioscler Thromb Vasc Biol. 2008;28:1237-1243; originally published online April 17, 2008;
doi: 10.1161/ATVBAHA.108.166454
Arteriosclerosis, Thrombosis, and Vascular Biology is published by the American Heart Association, 7272
Greenville Avenue, Dallas, TX 75231
Copyright © 2008 American Heart Association, Inc. All rights reserved.
Print ISSN: 1079-5642. Online ISSN: 1524-4636

The online version of this article, along with updated information and services, is located on the
World Wide Web at:
http://atvb.ahajournals.org/content/28/7/1237

Permissions: Requests for permissions to reproduce figures, tables, or portions of articles originally published
in Arteriosclerosis, Thrombosis, and Vascular Biology can be obtained via RightsLink, a service of the
Copyright Clearance Center, not the Editorial Office. Once the online version of the published article for
which permission is being requested is located, click Request Permissions in the middle column of the Web
page under Services. Further information about this process is available in the Permissions and Rights
Question and Answer document.

Reprints: Information about reprints can be found online at:
http://www.lww.com/reprints

Subscriptions: Information about subscribing to Arteriosclerosis, Thrombosis, and Vascular Biology is online
at:
http://atvb.ahajournals.org//subscriptions/